Background: Biomarkers for Alzheimer's disease (AD) in blood samples has the potential to facilitate early diagnosis and improve the accuracy of AD diagnosis. Plasma phosphorylated tau (p-tau) is a key biomarker for AD; however, its utility for estimating the prevalence of AD and screening for cognitive impairment is still limited.
Method: The study recruited 71 participants over the age of 40. Plasma p-tau 217 levels and neuropsychological data were measured. AD prevalence was estimated using a pre-defined cut-off derived from an independent cohort with biomarker-defined AD status according to the current framework (Jack et. al., 2018). The correlation between plasma p-tau 217 levels and neuropsychological data were also evaluated.
Result: The median age of participants was 62 years and overall clinical dementia rating of 0. The median Montreal cognitive assessment (MoCA) and Mini-Mental State Examination (MMSE) score was 26 and 29 consecutively. Plasma p-tau 217 levels showed a negative correlation with both neurocognitive tests (MoCA, Rho = -0.082, P = 0.5; MMSE, Rho = -0.26, P = 0.027). The estimated prevalence of AD was 16.9% (95% CI 9.9-27.3) when using plasma p-tau 217 as a biomarker, which was lower than the prevalence estimated using amyloid abnormalities of 30.1% (Jansen et. al., 2022).
Conclusion: The results of this study suggest the possibility of plasma p-tau 217 for estimating AD prevalence and cognition. It may represent those at risk of clinical onset. However, further studies are needed to investigate its utility in risk stratification, and cognitive performance assessment.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/alz.090601 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Biomarkers.
Alzheimers Dement
December 2024
Neurology Department, Hospital Universitario Marqués de Valdecilla - IDIVAL - University of Cantabria - CIBERNED, Madrid, Spain.
Background: Recent reports support the use of plasma biomarkers of neurodegeneration and neuroinflammation, as determined through ultrasensitive single molecular arrays (SIMOA), to screen and diagnose patients with dementia. However, their translation to clinical settings requires further studies.
Methods: We evaluated plasma samples from 186 individuals including 72 patients with AD (supported by CSF biomarkers consistent with an A+T+N+ classification scheme), 44 with confirmed FTD, 48 cognitively intact nonagenarians, and 22 controls (ages 40-83 years).
Background: Biomarkers, such as blood p-tau181, p-tau217, and p-tau231, have been created and verified to mirror the pathophysiology of tau and amyloid-β (Aβ) in the brain . Sleep spindles are known to contribute to memory consolidation and generalization and may therefore be a promising biomarker in preclinical Alzheimer's Disease (AD) . The present study investigated the relationship between sleep spindles and p-tau levels in cognitively healthy older African Americans.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of (South).
Background: We aimed to investigate whether the quantitative analysis of plasma biomarkers could distinguish the pathology stages indicated by positron emission tomography (PET)-based Thal phase of amyloid and Braak stage of tau.
Method: A total of 232 participants were enrolled, all of whom underwent F-florbetaben (FBB), F-flortaucipir (FTP) PET, plasma p-tau217/np-tau217 ratio, p-tau217, and Aβ ratio. To differentiate between image-based Thal phases and Braak stages, region-of-interests (ROIs) were constructed, and cut-off points were established at each stage using Gaussian mixture modeling.
Biomarkers.
Alzheimers Dement
December 2024
University of California San Francisco (UCSF), San Francisco, CA, USA.
Background: As new anti-amyloid immunotherapies emerge for Alzheimer's disease (AD), it is clear that early diagnosis of AD pathology is crucial for treatment success. This can be challenging in atypical presentations of AD and, together with our reliance on CSF or PET scans, can, at times, lead to delayed diagnosis. Here, we further explore the possible role of plasma tau phosphorylated at threonine 217 (P-tau217) for the detection of primary AD or AD co-pathology when frontotemporal dementia spectrum disorders are the main clinical presentation.
View Article and Find Full Text PDFBiomarkers.
Alzheimers Dement
December 2024
Thai Red Cross Emerging Infectious Diseases Health Science Centre, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Background: Biomarkers for Alzheimer's disease (AD) in blood samples has the potential to facilitate early diagnosis and improve the accuracy of AD diagnosis. Plasma phosphorylated tau (p-tau) is a key biomarker for AD; however, its utility for estimating the prevalence of AD and screening for cognitive impairment is still limited.
Method: The study recruited 71 participants over the age of 40.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!